5-HT1B receptor binding in degenerative movement disorders

Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls. In the control human basal ganglia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 1998-04, Vol.790 (1-2), p.323-328
Hauptverfasser: CASTRO, M. E, PASCUAL, J, ROMON, T, BERCIANO, J, FIGOLS, J, PAZOS, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 328
container_issue 1-2
container_start_page 323
container_title Brain research
container_volume 790
creator CASTRO, M. E
PASCUAL, J
ROMON, T
BERCIANO, J
FIGOLS, J
PAZOS, A
description Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls. In the control human basal ganglia, the highest densities of [3H]sumatriptan binding were observed in the globus pallidus and substantia nigra. No significant change in the density of [3H]sumatriptan binding sites was found in the striatum and substantia nigra of the six Parkinson's disease brains. In the two brains from patients with progressive supranuclear palsy an increase was found in the densities of [3H]sumatriptan binding sites, most marked in the substantia nigra. In contrast, [3H]sumatriptan labelling was almost absent in the striatonigral degeneration brain and was markedly reduced in the three Huntington's disease brains. This study indicates that the status of 5-HT1B receptors is different in each degenerative movement disorder and suggests that human 5-HT1B receptors are located somatodendritically on GABAergic and peptidergic caudate-putamen neurons which project to the substantia nigra and globus pallidus, where these receptors are presynaptic.
doi_str_mv 10.1016/S0006-8993(97)01566-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79878476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79878476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c265t-5543858f8cf40d62f44e59785013111899c5bc1e38aa1cf15327d6ca302bb8ed3</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMotVZ_QmEPInpYzcfmy5sWtULBg_UcsslsiexHTbYF_73bWnoahnnemeFBaErwPcFEPHxijEWutGa3Wt5hwoXI5QkaEyVpLmiBT9H4iJyji5S-h5YxjUdopLlmWpIxeuT5fEmeswgO1n0XszK0PrSrLLSZhxW0EG0ftpA13RYaaPvMh9RFDzFdorPK1gmuDnWCvl5flrN5vvh4e589LXJHBe9zzgumuKqUqwrsBa2KAriWimPCCCHDd46XjgBT1hJXEc6o9MJZhmlZKvBsgm7-965j97OB1JsmJAd1bVvoNslIraQqpBhA_g-62KUUoTLrGBobfw3BZufM7J2ZnRCjpdk7M3LITQ8HNmUD_pg6SBrm14e5Tc7WVbStC-mIUcq5KjD7Ax2-co0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79878476</pqid></control><display><type>article</type><title>5-HT1B receptor binding in degenerative movement disorders</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>CASTRO, M. E ; PASCUAL, J ; ROMON, T ; BERCIANO, J ; FIGOLS, J ; PAZOS, A</creator><creatorcontrib>CASTRO, M. E ; PASCUAL, J ; ROMON, T ; BERCIANO, J ; FIGOLS, J ; PAZOS, A</creatorcontrib><description>Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls. In the control human basal ganglia, the highest densities of [3H]sumatriptan binding were observed in the globus pallidus and substantia nigra. No significant change in the density of [3H]sumatriptan binding sites was found in the striatum and substantia nigra of the six Parkinson's disease brains. In the two brains from patients with progressive supranuclear palsy an increase was found in the densities of [3H]sumatriptan binding sites, most marked in the substantia nigra. In contrast, [3H]sumatriptan labelling was almost absent in the striatonigral degeneration brain and was markedly reduced in the three Huntington's disease brains. This study indicates that the status of 5-HT1B receptors is different in each degenerative movement disorder and suggests that human 5-HT1B receptors are located somatodendritically on GABAergic and peptidergic caudate-putamen neurons which project to the substantia nigra and globus pallidus, where these receptors are presynaptic.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/S0006-8993(97)01566-7</identifier><identifier>PMID: 9593971</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>London: Elsevier</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Corpus Striatum - chemistry ; Corpus Striatum - pathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Humans ; Huntington Disease - metabolism ; Huntington Disease - pathology ; Male ; Medical sciences ; Middle Aged ; Movement Disorders - metabolism ; Movement Disorders - pathology ; Nerve Degeneration - metabolism ; Nerve Degeneration - pathology ; Neurology ; Parkinson Disease - metabolism ; Parkinson Disease - pathology ; Radioligand Assay ; Receptor, Serotonin, 5-HT1B ; Receptors, Serotonin - analysis ; Receptors, Serotonin - metabolism ; Serotonin Receptor Agonists - metabolism ; Serotonin Receptor Agonists - pharmacology ; Substantia Nigra - chemistry ; Substantia Nigra - pathology ; Sumatriptan - metabolism ; Sumatriptan - pharmacology ; Supranuclear Palsy, Progressive - metabolism ; Supranuclear Palsy, Progressive - pathology ; Tritium</subject><ispartof>Brain research, 1998-04, Vol.790 (1-2), p.323-328</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright 1998 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c265t-5543858f8cf40d62f44e59785013111899c5bc1e38aa1cf15327d6ca302bb8ed3</citedby><cites>FETCH-LOGICAL-c265t-5543858f8cf40d62f44e59785013111899c5bc1e38aa1cf15327d6ca302bb8ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2255840$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9593971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CASTRO, M. E</creatorcontrib><creatorcontrib>PASCUAL, J</creatorcontrib><creatorcontrib>ROMON, T</creatorcontrib><creatorcontrib>BERCIANO, J</creatorcontrib><creatorcontrib>FIGOLS, J</creatorcontrib><creatorcontrib>PAZOS, A</creatorcontrib><title>5-HT1B receptor binding in degenerative movement disorders</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls. In the control human basal ganglia, the highest densities of [3H]sumatriptan binding were observed in the globus pallidus and substantia nigra. No significant change in the density of [3H]sumatriptan binding sites was found in the striatum and substantia nigra of the six Parkinson's disease brains. In the two brains from patients with progressive supranuclear palsy an increase was found in the densities of [3H]sumatriptan binding sites, most marked in the substantia nigra. In contrast, [3H]sumatriptan labelling was almost absent in the striatonigral degeneration brain and was markedly reduced in the three Huntington's disease brains. This study indicates that the status of 5-HT1B receptors is different in each degenerative movement disorder and suggests that human 5-HT1B receptors are located somatodendritically on GABAergic and peptidergic caudate-putamen neurons which project to the substantia nigra and globus pallidus, where these receptors are presynaptic.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Corpus Striatum - chemistry</subject><subject>Corpus Striatum - pathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Huntington Disease - metabolism</subject><subject>Huntington Disease - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Movement Disorders - metabolism</subject><subject>Movement Disorders - pathology</subject><subject>Nerve Degeneration - metabolism</subject><subject>Nerve Degeneration - pathology</subject><subject>Neurology</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - pathology</subject><subject>Radioligand Assay</subject><subject>Receptor, Serotonin, 5-HT1B</subject><subject>Receptors, Serotonin - analysis</subject><subject>Receptors, Serotonin - metabolism</subject><subject>Serotonin Receptor Agonists - metabolism</subject><subject>Serotonin Receptor Agonists - pharmacology</subject><subject>Substantia Nigra - chemistry</subject><subject>Substantia Nigra - pathology</subject><subject>Sumatriptan - metabolism</subject><subject>Sumatriptan - pharmacology</subject><subject>Supranuclear Palsy, Progressive - metabolism</subject><subject>Supranuclear Palsy, Progressive - pathology</subject><subject>Tritium</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEQhoMotVZ_QmEPInpYzcfmy5sWtULBg_UcsslsiexHTbYF_73bWnoahnnemeFBaErwPcFEPHxijEWutGa3Wt5hwoXI5QkaEyVpLmiBT9H4iJyji5S-h5YxjUdopLlmWpIxeuT5fEmeswgO1n0XszK0PrSrLLSZhxW0EG0ftpA13RYaaPvMh9RFDzFdorPK1gmuDnWCvl5flrN5vvh4e589LXJHBe9zzgumuKqUqwrsBa2KAriWimPCCCHDd46XjgBT1hJXEc6o9MJZhmlZKvBsgm7-965j97OB1JsmJAd1bVvoNslIraQqpBhA_g-62KUUoTLrGBobfw3BZufM7J2ZnRCjpdk7M3LITQ8HNmUD_pg6SBrm14e5Tc7WVbStC-mIUcq5KjD7Ax2-co0</recordid><startdate>19980420</startdate><enddate>19980420</enddate><creator>CASTRO, M. E</creator><creator>PASCUAL, J</creator><creator>ROMON, T</creator><creator>BERCIANO, J</creator><creator>FIGOLS, J</creator><creator>PAZOS, A</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980420</creationdate><title>5-HT1B receptor binding in degenerative movement disorders</title><author>CASTRO, M. E ; PASCUAL, J ; ROMON, T ; BERCIANO, J ; FIGOLS, J ; PAZOS, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c265t-5543858f8cf40d62f44e59785013111899c5bc1e38aa1cf15327d6ca302bb8ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Corpus Striatum - chemistry</topic><topic>Corpus Striatum - pathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Huntington Disease - metabolism</topic><topic>Huntington Disease - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Movement Disorders - metabolism</topic><topic>Movement Disorders - pathology</topic><topic>Nerve Degeneration - metabolism</topic><topic>Nerve Degeneration - pathology</topic><topic>Neurology</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - pathology</topic><topic>Radioligand Assay</topic><topic>Receptor, Serotonin, 5-HT1B</topic><topic>Receptors, Serotonin - analysis</topic><topic>Receptors, Serotonin - metabolism</topic><topic>Serotonin Receptor Agonists - metabolism</topic><topic>Serotonin Receptor Agonists - pharmacology</topic><topic>Substantia Nigra - chemistry</topic><topic>Substantia Nigra - pathology</topic><topic>Sumatriptan - metabolism</topic><topic>Sumatriptan - pharmacology</topic><topic>Supranuclear Palsy, Progressive - metabolism</topic><topic>Supranuclear Palsy, Progressive - pathology</topic><topic>Tritium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CASTRO, M. E</creatorcontrib><creatorcontrib>PASCUAL, J</creatorcontrib><creatorcontrib>ROMON, T</creatorcontrib><creatorcontrib>BERCIANO, J</creatorcontrib><creatorcontrib>FIGOLS, J</creatorcontrib><creatorcontrib>PAZOS, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CASTRO, M. E</au><au>PASCUAL, J</au><au>ROMON, T</au><au>BERCIANO, J</au><au>FIGOLS, J</au><au>PAZOS, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5-HT1B receptor binding in degenerative movement disorders</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1998-04-20</date><risdate>1998</risdate><volume>790</volume><issue>1-2</issue><spage>323</spage><epage>328</epage><pages>323-328</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>Using [3H]sumatriptan as a radioligand, 5-hydroxytryptamine (5-HT)1B receptors were examined in posterior striatum and midbrain post-mortem tissue sections of 12 patients who had died from representative degenerative movement disorders as compared to nine controls. In the control human basal ganglia, the highest densities of [3H]sumatriptan binding were observed in the globus pallidus and substantia nigra. No significant change in the density of [3H]sumatriptan binding sites was found in the striatum and substantia nigra of the six Parkinson's disease brains. In the two brains from patients with progressive supranuclear palsy an increase was found in the densities of [3H]sumatriptan binding sites, most marked in the substantia nigra. In contrast, [3H]sumatriptan labelling was almost absent in the striatonigral degeneration brain and was markedly reduced in the three Huntington's disease brains. This study indicates that the status of 5-HT1B receptors is different in each degenerative movement disorder and suggests that human 5-HT1B receptors are located somatodendritically on GABAergic and peptidergic caudate-putamen neurons which project to the substantia nigra and globus pallidus, where these receptors are presynaptic.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier</pub><pmid>9593971</pmid><doi>10.1016/S0006-8993(97)01566-7</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 1998-04, Vol.790 (1-2), p.323-328
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_79878476
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Aged
Aged, 80 and over
Biological and medical sciences
Corpus Striatum - chemistry
Corpus Striatum - pathology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Humans
Huntington Disease - metabolism
Huntington Disease - pathology
Male
Medical sciences
Middle Aged
Movement Disorders - metabolism
Movement Disorders - pathology
Nerve Degeneration - metabolism
Nerve Degeneration - pathology
Neurology
Parkinson Disease - metabolism
Parkinson Disease - pathology
Radioligand Assay
Receptor, Serotonin, 5-HT1B
Receptors, Serotonin - analysis
Receptors, Serotonin - metabolism
Serotonin Receptor Agonists - metabolism
Serotonin Receptor Agonists - pharmacology
Substantia Nigra - chemistry
Substantia Nigra - pathology
Sumatriptan - metabolism
Sumatriptan - pharmacology
Supranuclear Palsy, Progressive - metabolism
Supranuclear Palsy, Progressive - pathology
Tritium
title 5-HT1B receptor binding in degenerative movement disorders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A27%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5-HT1B%20receptor%20binding%20in%20degenerative%20movement%20disorders&rft.jtitle=Brain%20research&rft.au=CASTRO,%20M.%20E&rft.date=1998-04-20&rft.volume=790&rft.issue=1-2&rft.spage=323&rft.epage=328&rft.pages=323-328&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/S0006-8993(97)01566-7&rft_dat=%3Cproquest_cross%3E79878476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79878476&rft_id=info:pmid/9593971&rfr_iscdi=true